The 8th JBSA Annual Conference
December 11, 12 2008
Senri Life Science Center Building, Exhibision & Meeting Hall
1-4-2 Shin-Senri-Higashimachi, Toyonaka-shi, Osaka 560-0082, Japan

December 11
9:30- 9:35

Opening Remark

Educational Lectures
The current situation and problem of proper
9:35-10:05 management of pathogenic agents based on
the infectious disease law
The current situation of transportation of
10:05-10:25
pathogenic agents and and problem
About the transportation of Pathogenic agents
10:25-10:35 under the Japanese Infectious Diseases
Control Law and Category B handling.
10:35-10:45 Break (10min)
Session I
Disinfection
Sterilization and disinfection of clinicalinstruments
Fair is foul, and foul is fair. Is disinfection of
11:05-11:25
human possible, and necessary ?
10:45-11:05

11:25-11:45 Sterilization in dentistry
11:45-13:05 Lunch (80mim)
13:05-13:30 General Meetnig
Session II
Current Situation for Biosafety in Asia
13:30-13:50 Approach to biosafety by WHO WPROJICA Course "Biosafety control for emerging
13:50-14:40 infectious diseases for Asia"
Country report

14:40-15:00 Discussion
15:00-15:10 Break (10min)

Chairman of the meeting:Koichi Yamanishi
National Institute of Biomedical Innovation
Chair:
Tetsutaro Sata1), Yuko Sagara2)
1)
National Institute of Infectious Diseases
2)
Yokohama Municipal Citizen's Hospital
Hiroshi Umeda
Ministry of Health, Labour and Welfare
Shuji Ando
National Institute of Infectious Diseases
Kiyoshi Mamizuka
Nippon Express Co.,Ltd.
Chair:
Hak Hotta1), Kentaro Iwata2)
1)
Kobe University Graduate School of Medicine
2)
Kobe University Hospital
Kouichi Sano, Takashi Nakano
Osaka Medical CollegeKentaro Iwata
Kobe University Hospital
Shigefumi Okamoto
National Institute of Biomedical Innovation
Chair:
Kazuyoshi SugiyamaNational Institute of Infectious Diseases
Kazuyoshi Sugiyama
National Institute of Infectious Diseases
Ms. RAMADHANY Ririn1)
Mr. SOMOULAY Virasack2)
Ms. KHURELSUKH Tungalag3)
Dr. YIN Yin Htwe4)
Ms. VEERASEATAKUL Punnarai5)
1)
Indonesia, NIHRD
2)
Laos, NCLE
3)
Mongolia, NCID
4)
Myanmar, NHL
5)
Thailand, RMSCC

Chair:Takeshi Kurata1), Ichiro Kurane2)
Symposium
1)
Why Japan needs BSL4 facilities ?
Toyama Institute of Health2)
National Institute of Infectious Diseases
Eiji Marui
15:10-15:40 Role of risk communication and its potentialityJuntendo University
The biology of Influenza virus - ForHiroshi Kida
15:40-16:10
appearance of new type virus Hokkaido University
BSL4 facility design and management forKazuyoshi Sugiyama
16:10-16:40
maintenance
National Institute of Infectious Diseases
Ichiro Kurane
16:40-17:10 Why Japan needs BSL4 facilities ?
National Institute of Infectious Diseases［Poster ･ Exhibition］
Verification of formaldehyde gas concentration Naoya Sasaki
during decontamination
Mercian Cleantec Corporation
9:30-17:00
Study on antiviral and antibacterial activity of Takanori Miurachlorine dioxide solution
Taiko Pharmaceutical Co.,Ltd.

December 12

Applied subjects (Oral presentation)

Chair:
Kazuo Takahashi1), Takaaki Nakaya2)
1)
Osaka Prefectural Institute of Public Health2)
Research Institute for Microbial Diseases,
Osaka University

Shigeo Iki
National Institute of Infectious Diseases
Norio Ogata
Effect of low-concentration chlorine dioxide gas
Takashi Shibata
9:45- 10:00
against influenza virus
Taiko Pharmaceutical Co.,Ltd.
9:30- 9:45

Training for biological safety in National
Institute of Infectious Diseases

Research on stabilization of inflow velocity of
10:00-10:15 Class II biological safety cabinets of method
exhausted to outdoor

Keiichi Ono1), Masaya Ishihara2)
1)
Hitachi Appliance Inc.
2)
Yamatake Corporation

Development of technologies for air
Matsuo Kamitani
10:15-10:30 conditioning facilities of higher performance in
Hitachi Plant Technologies, Ltd.
Experimental Animal Care Facilitiy
Shiro Wada
10:30-10:45 Environmental maintenance in Glove-Box
Miwa MFG Co., Ltd.
10:45-11:00 Break (15min)
Chair:
Session III
Atsuo Kitabayashi
Biosafety Facilities
Yashima
Collaboration plan for two bio research
Ippei Miyamoto
11:00-11:20
institutes
Yamashita Sekkei Inc.
Katsuaki Shinohara
11:20-11:40 Biosafety guideline, schedule
National Institute of Infectious Diseases
Chair:
Hak Hotta Sata1), Kentaro Iwata2)
Session I1)
Disinfection
Kobe University Graduate School of Medicine2)
Kobe University Hospital
Takeshi Okubo
Inactivation of the Creutzfeldt-Jakob disease
11:40-12:00
Tokyo Healthcare University Postgraduate(CJD) prion
School
12:00-13:00 Lunch (60mim)
Chair:
Session IV
Kazunori Asano1), Aikichi Iwamoto2)
Present situation and problem for countermeasure for1)
Osaka University Hospitalbiohazard in medical facilities
2)
Institute of Medical Science
Seishi Asari
13:00-13:20 Biosafety control in microbiological laboratory
Osaka University Hospital
Amendment of IDCL and correspondense ofMitsuaki Nagasawa
13:20-13:40
microbiological diagnostic lab and probrem
Tohoku University Hospital
Biorisk management in hospital pathology
13:40-14:00
division
The current issue of biosafety in hospital
infection control and prevention
14:20-14:30 Break (10min)
14:00-14:20

Tetsutaro Sata
Harutaka Katano
Minoru Tobiume
National Institute of Infectious Diseases
Yosuke Aoki
Saga University Medical CenterSession V
Experimental Animal

Introduction of AAALAC International
accreditation of biosafety facilities
Management of animal experimentation for
14:50-15:10
infectious diseases
14:30-14:50

15:10-15:30

Development of new TB vaccine using
experimental animal

15:30-15:50

Biosafety in research of non-human primate
models on human infectious diseases

Chair:
Tsutomu Miki Kurosawa1),
Yasuhiro Yoshikawa2)
1)
Osaka University Medical School
2)
The University of Tokyo
Tsutomu Miki Kurosawa
Osaka University Medical School
Masahito Ikawa
Osaka University
Masaji Okada
National Hospital Organization Kinki-Chuo
Chest Medical Center
Hirofumi Akari
Tsukuba Primate Research Center, National
Institute of Biomedical Innovation［Poster ･ Exhibition］
Verification of formaldehyde gas concentration Naoya Sasaki
during decontamination
Mercian Cleantec Corporation
9:30-15:50
Study on antiviral and antibacterial activity of Takanori Miurachlorine dioxide solution
Taiko Pharmaceutical Co.,Ltd.